PUBLISHER: The Business Research Company | PRODUCT CODE: 1826982
PUBLISHER: The Business Research Company | PRODUCT CODE: 1826982
Radiotherapy-induced oral mucositis treatment involves medical interventions aimed at managing and alleviating the painful condition of oral mucositis caused by radiotherapy. These treatments focus on reducing inflammation, preventing infection, relieving pain, and promoting healing of the mucosal tissues in the mouth, which are damaged during cancer treatments, especially in patients receiving radiotherapy for head and neck cancers.
The primary drug classes used in treating radiotherapy-induced oral mucositis include antibiotics, antifungals, anti-inflammatory agents, and anti-neoplastic drugs. Antibiotics help prevent or treat bacterial infections by either killing the bacteria or inhibiting their growth. Treatment options include topical agents, systemic medications, and medical devices. Radiotherapy techniques used in treatment include external beam radiation therapy (EBRT), intensity-modulated radiation therapy (IMRT), brachytherapy, proton therapy, stereotactic radiosurgery (SRS), and others. The severity of oral mucositis is categorized as mild, moderate, or severe. This treatment is typically administered in hospitals, oncology centers, research institutes, and dental clinics.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The radiotherapy induced oral mucositis treatment market research report is one of a series of new reports from The Business Research Company that provides radiotherapy induced oral mucositis treatment market statistics, including the radiotherapy induced oral mucositis treatment industry's global market size, regional shares, competitors with a radiotherapy induced oral mucositis treatment market share, detailed radiotherapy induced oral mucositis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the radiotherapy induced oral mucositis treatment industry. This radiotherapy induced oral mucositis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The radiotherapy induced oral mucositis treatment market size has grown strongly in recent years. It will grow from $1.76 billion in 2024 to $1.85 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to an increase in the incidence of cancer globally, growth in awareness about oral mucositis, a rise in the prevalence of head and neck cancers, an expansion of healthcare infrastructure, and a rise in demand for supportive care solutions.
The radiotherapy induced oral mucositis treatment market size is expected to see strong growth in the next few years. It will grow to $2.25 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to increasing adoption of regenerative medicine approaches, rising incidence of radiotherapy, rising prevalence of chronic diseases, expansion of telehealth services, and rising demand for home-based care solutions. Major trends in the forecast period include advancements in intensity modulated radiotherapy techniques, development of targeted therapies, integration of telemedicine, development of personalized medicine approaches, and advancements in imaging techniques.
The forecast of 5.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. patient access to compounded mucosal barrier gels by inflating prices of hyaluronic acid and keratinocyte growth factors developed in Ireland and Singapore, resulting in prolonged pain management and higher supportive care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising global prevalence of cancer is expected to drive the growth of the radiotherapy-induced oral mucositis treatment market. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells, which can invade surrounding tissues and organs. This condition arises from genetic mutations influenced by environmental and lifestyle factors. The increasing global prevalence of cancer is largely attributed to factors such as an aging population, lifestyle choices such as tobacco use, obesity, and alcohol consumption, as well as environmental influences such as air pollution. Radiotherapy-induced oral mucositis treatment helps cancer patients manage the painful side effects of mucosal damage caused by radiotherapy, allowing them to better tolerate treatment and maintain proper nutritional intake, which ultimately improves their quality of life during cancer care. For example, in August 2024, Macmillan Cancer Support, a UK-based charitable organization, reported that more than 3 million people in the UK were living with cancer in 2024, and this number is projected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the rising global prevalence of cancer is driving the growth of the radiotherapy-induced oral mucositis treatment market.
Leading companies in the radiotherapy-induced oral mucositis treatment market are focusing on developing innovative products, such as low-level laser therapy, to accelerate healing, reduce pain, and improve patient outcomes during cancer treatment. Low-level laser therapy, also known as cold laser therapy or photobiomodulation, is a non-invasive treatment that uses low-power lasers or light-emitting diodes (LEDs) to stimulate healing and reduce pain and inflammation. For example, in October 2024, Jaguar Health Inc., a US-based pharmaceutical company, launched Gelclair, an oral mucositis prescription gel. Specifically designed to manage the pain associated with oral mucositis, a condition that affects up to 90% of head and neck cancer patients undergoing chemotherapy and radiotherapy, Gelclair adheres to the mucosal surface of the mouth, providing rapid and long-lasting pain relief without the stinging or numbing effects typically associated with other treatments.
In September 2024, InfuSystem Holdings Inc., a US-based healthcare services company, partnered with ChemoMouthpiece LLC. This partnership enables InfuSystem to exclusively distribute the Chemo Mouthpiece in the United States, aiming to reduce the incidence and severity of oral mucositis in cancer patients undergoing chemotherapy and radiotherapy. ChemoMouthpiece LLC is a US-based company offering a treatment for radiotherapy-induced oral mucositis.
Major players in the radiotherapy induced oral mucositis treatment market are Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Zydus Cadila Health Care Limited, Leo Pharma A/S, Glenmark Pharmaceuticals Ltd., Almirall S.A., Fagron Group BV, Sage Products LLC, Soligenix Inc., EUSA Pharma Ltd., Galera Therapeutics Inc., Enzychem Lifesciences Corp., Jaguar Health Inc., EpicentRx Inc., MONOPAR Therapeutics Inc., Solasia Pharma KK, Cellceutix Corporation, Innovation Pharmaceuticals Inc.
North America was the largest region in the radiotherapy induced oral mucositis treatment market in 2024. The regions covered in radiotherapy induced oral mucositis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the radiotherapy induced oral mucositis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The radiotherapy-induced oral mucositis treatment market includes revenues earned by entities by providing services such as symptom management, cryotherapy, wound care and healing support, and pharmacological interventions and related products, including mouthwashes and rinses, topical gels and creams, oral sprays, and hydrogels and hydrating agents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Radiotherapy Induced Oral Mucositis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on radiotherapy induced oral mucositis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for radiotherapy induced oral mucositis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The radiotherapy induced oral mucositis treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.